Chelsea Counsel Company’s Vertex Pharmaceuticals VRTX Stock Holding History

Chelsea Counsel Company’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$74.5K	Hold	150	–	–	0.03%	128
2026 Q1	$67K	Hold	150	–	–	0.03%	127
2025 Q4	$68K	Hold	150	–	–	0.03%	122
2025 Q3	$58.7K	Hold	150	–	–	0.03%	130
2025 Q2	$66.8K	Hold	150	–	–	0.03%	127
2025 Q1	$72.7K	Hold	150	–	–	0.04%	121
2024 Q4	$60.4K	Hold	150	–	–	0.03%	125
2024 Q3	$69.8K	Hold	150	–	–	0.03%	125
2024 Q2	$70.3K	Buy	+150	New	+$65.1K	0.04%	118
2015 Q2	–	Sell	-2,300	Closed	-$271K	–	167
2015 Q1	$271K	Hold	2,300	–	–	0.06%	115
2014 Q4	$273K	Buy	+2,300	New	+$259K	0.06%	113

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Chelsea Counsel Company's VRTX Position: Q2 2026 in Review

Chelsea Counsel Company held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2026 at 150 shares worth $74.5K. The position accounts for 0.03% of the portfolio, ranked #128.

Chelsea Counsel Company first reported a position in VRTX in Q4 2014 and has held it in 11 quarters since. The position peaked at $273K in Q4 2014. 1,761 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Chelsea Counsel Company held 150 shares of Vertex Pharmaceuticals worth $74.5K as of Q2 2026.
Chelsea Counsel Company left its Vertex Pharmaceuticals share count unchanged in Q2 2026.
Vertex Pharmaceuticals made up 0.03% of Chelsea Counsel Company's portfolio in Q2 2026, its #128 holding.
Chelsea Counsel Company first reported a position in Vertex Pharmaceuticals in Q4 2014 and has held it in 11 quarters since.
Chelsea Counsel Company's Vertex Pharmaceuticals position peaked at $273K in Q4 2014.
1,761 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Chelsea Counsel Company's 13F filing for Q2 2026, filed 12 Aug 2026.